Background: Fufang HuangQi granule (FFHQ), a traditional Chinese medicine formula, has shown clinical efficacy in treating myasthenia gravis; however, the underlying mechanisms remain unclear. This study aimed to explore the therapeutic effects of FFHQ in an experimental autoimmune myasthenia gravis (EAMG) rat model and to elucidate its therapeutic mechanisms. Methods: The EAMG rat model was established, and the rats were treated with FFHQ. The therapeutic effects were evaluated through several indicators, including grip strength, clinical scoring, serum anti-AChR antibody levels, and muscle histopathology. RNA sequencing analysis was subsequently performed on muscle tissues, and a network pharmacology approach was applied to FFHQ. Finally, the mechanisms were further validated by quantitative real-time PCR and immunohistochemistry. Results: FFHQ ameliorated the decrease in muscle grip strength and the increases in clinical scores and serum anti-AChR antibody levels while simultaneously alleviating muscle inflammation symptoms in EAMG rats. As suggested by the RNA-seq and network pharmacology analyses, its efficacy may be associated with the regulation of the IL-17 signaling pathway. RT-qPCR studies revealed that the levels of Tgfb, Il6, Il1a, Il17a, Nfkb1, Rela, Cxcl2, Cxcl6, and Ccl17 were significantly increased in EAMG rats but decreased after treatment. Immunohistochemical analysis of muscle sections further confirmed a significant reduction in IL-17A expression in the FFHQ administration group compared to the control group. Conclusion: FFHQ improved symptoms in EAMG rats, exerting beneficial effects by modulating the IL-17 signaling pathway. These findings offer a theoretical basis for its utilization.